user
menu
letter
Sign InRegister
langEnglisharrow

Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Complex Protein (Monomer, MALS verified)

製品番号/仕様
価格
Availability
数量
HLT-H82E9-25ug
$125.00
In Stock - Delivery in 1-2 business days
HLT-H82E9-200ug
$700.00
In Stock - Delivery in 2-3 weeks
HLT-H82E9
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
Request Quote
製品詳細
データ表示
Reviews & Citations
Resources
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

HLA-A*0201 & B2M & HBV (FLLTRILTI)

Source

Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Complex Protein (HLT-H82E9) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & FLLTRILTI peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & FLLTRILTI).

Predicted N-terminus: Gly 25 & Ile 21

Molecular Characterization

Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Complex Protein is produced by co-expression of HLA and B2M loaded with HBV peptide.

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-42 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 3 months under sterile conditions.
ACRO Quality Management System

バックグランド

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). The hepatitis B virus attacks the liver and can cause both acute and chronic diseases that put people at high risk of death from cirrhosis and liver cancer. The virus is most commonly transmitted from mother to child during birth and delivery, as well as through contact with blood or other body fluids. Hepatitis B virus (HBV) is a member of the hepadnaviral family. The virus particle (virion) consists of an outer lipid envelope and an icosahedral nucleocapsid core composed of the core protein. The nucleocapsid encloses the viral D and a D polymerase that has reverse transcriptase activity. The outer envelope contains embedded proteins that are involved in viral binding of, and entry into, susceptible cells. The surface antigens (HBsAg) decorating the lipid envelope of HBV are produced in excess during the life cycle of the virus, and its presence in blood indicates current hepatitis B infection. The Human HLA-A*0201 HBV ( FLLTRILTI) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and FLLTRILTI peptide of the HBV.